Research ExplorerPublicationsIs reduced expression of mismatch repair genes MLH1 and MSH2...

Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis?

Standard

Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? / Kruschewski, Martin; Noske, Aurelia; Haier, Jörg; Runkel, Norbert; Anagnostopoulos, Yanis; Buhr, Heinz Johannes.

In: CLIN EXP METASTAS, Vol. 19, No. 1, 2002, p. 71-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kruschewski, M, Noske, A, Haier, J, Runkel, N, Anagnostopoulos, Y & Buhr, HJ 2002, 'Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis?', CLIN EXP METASTAS, vol. 19, no. 1, pp. 71-7.

APA

Kruschewski, M., Noske, A., Haier, J., Runkel, N., Anagnostopoulos, Y., & Buhr, H. J. (2002). Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? CLIN EXP METASTAS, 19(1), 71-7.

Vancouver

Kruschewski M, Noske A, Haier J, Runkel N, Anagnostopoulos Y, Buhr HJ. Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? CLIN EXP METASTAS. 2002;19(1):71-7.

Bibtex

@article{50e533130a9e4693a7c11fed12871ec7,
title = "Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis?",
abstract = "The majority of mutations in hereditary nonpolyposis colon carcinoma (HNPCC) patients affect the mismatch-repair genes (MMRG) MLHI and MSH2. In addition, mutations of these genes were found in about 15% of sporadic colorectal carcinomas which appear to be related to microsatellite instability (MSI). However, mutations in MMRG were not found in all MSI-positive carcinomas, but MMRG mutations may be relevant for the assessment of tumor characteristics and patients' prognosis. Therefore, we investigated the relationship between expression of MMRG, tumor biology and patients' survival. In 127 patients with sporadic colorectal carcinomas and a minimum of 5 years follow-up after curative surgery immunohistochemical detection of MLHI and MSH2 was analyzed semiquantitatively. Lost expression of MLHI has been found in tumor specimens from 10 patients, whereas MSH2 expression was missing in 5 patients. This reduced expression did not correlate with tumor stage, lymph node involvement, grading or tumor invasion into blood vessels. However, a significant correlation was found for lymphovascular invasion (P = 0.02) and localization within the colorectum (P = 0.003) in MLH1-negative carcinomas. In addition, although there was a clear tendency for longer overall survival (72 vs. 63 months) for patients with MLH1-negative carcinomas, significant differences for overall and recurrence-free survival were not seen. In conclusion of our results and a critical review of literature, the prognostic importance of the MMR genes in sporadic colorectal carcinomas remains controversial.",
keywords = "Adaptor Proteins, Signal Transducing, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Base Pair Mismatch, Carrier Proteins, Colorectal Neoplasms, DNA Mutational Analysis, DNA Repair, DNA, Neoplasm, DNA-Binding Proteins, Disease-Free Survival, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Life Tables, Male, Middle Aged, MutS Homolog 2 Protein, Neoplasm Proteins, Neoplasm Staging, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Survival Analysis",
author = "Martin Kruschewski and Aurelia Noske and J{\"o}rg Haier and Norbert Runkel and Yanis Anagnostopoulos and Buhr, {Heinz Johannes}",
year = "2002",
language = "English",
volume = "19",
pages = "71--7",
journal = "CLIN EXP METASTAS",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "1",

}

RIS

TY - JOUR

T1 - Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis?

AU - Kruschewski, Martin

AU - Noske, Aurelia

AU - Haier, Jörg

AU - Runkel, Norbert

AU - Anagnostopoulos, Yanis

AU - Buhr, Heinz Johannes

PY - 2002

Y1 - 2002

N2 - The majority of mutations in hereditary nonpolyposis colon carcinoma (HNPCC) patients affect the mismatch-repair genes (MMRG) MLHI and MSH2. In addition, mutations of these genes were found in about 15% of sporadic colorectal carcinomas which appear to be related to microsatellite instability (MSI). However, mutations in MMRG were not found in all MSI-positive carcinomas, but MMRG mutations may be relevant for the assessment of tumor characteristics and patients' prognosis. Therefore, we investigated the relationship between expression of MMRG, tumor biology and patients' survival. In 127 patients with sporadic colorectal carcinomas and a minimum of 5 years follow-up after curative surgery immunohistochemical detection of MLHI and MSH2 was analyzed semiquantitatively. Lost expression of MLHI has been found in tumor specimens from 10 patients, whereas MSH2 expression was missing in 5 patients. This reduced expression did not correlate with tumor stage, lymph node involvement, grading or tumor invasion into blood vessels. However, a significant correlation was found for lymphovascular invasion (P = 0.02) and localization within the colorectum (P = 0.003) in MLH1-negative carcinomas. In addition, although there was a clear tendency for longer overall survival (72 vs. 63 months) for patients with MLH1-negative carcinomas, significant differences for overall and recurrence-free survival were not seen. In conclusion of our results and a critical review of literature, the prognostic importance of the MMR genes in sporadic colorectal carcinomas remains controversial.

AB - The majority of mutations in hereditary nonpolyposis colon carcinoma (HNPCC) patients affect the mismatch-repair genes (MMRG) MLHI and MSH2. In addition, mutations of these genes were found in about 15% of sporadic colorectal carcinomas which appear to be related to microsatellite instability (MSI). However, mutations in MMRG were not found in all MSI-positive carcinomas, but MMRG mutations may be relevant for the assessment of tumor characteristics and patients' prognosis. Therefore, we investigated the relationship between expression of MMRG, tumor biology and patients' survival. In 127 patients with sporadic colorectal carcinomas and a minimum of 5 years follow-up after curative surgery immunohistochemical detection of MLHI and MSH2 was analyzed semiquantitatively. Lost expression of MLHI has been found in tumor specimens from 10 patients, whereas MSH2 expression was missing in 5 patients. This reduced expression did not correlate with tumor stage, lymph node involvement, grading or tumor invasion into blood vessels. However, a significant correlation was found for lymphovascular invasion (P = 0.02) and localization within the colorectum (P = 0.003) in MLH1-negative carcinomas. In addition, although there was a clear tendency for longer overall survival (72 vs. 63 months) for patients with MLH1-negative carcinomas, significant differences for overall and recurrence-free survival were not seen. In conclusion of our results and a critical review of literature, the prognostic importance of the MMR genes in sporadic colorectal carcinomas remains controversial.

KW - Adaptor Proteins, Signal Transducing

KW - Adenocarcinoma

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Base Pair Mismatch

KW - Carrier Proteins

KW - Colorectal Neoplasms

KW - DNA Mutational Analysis

KW - DNA Repair

KW - DNA, Neoplasm

KW - DNA-Binding Proteins

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Life Tables

KW - Male

KW - Middle Aged

KW - MutS Homolog 2 Protein

KW - Neoplasm Proteins

KW - Neoplasm Staging

KW - Nuclear Proteins

KW - Prognosis

KW - Proto-Oncogene Proteins

KW - Survival Analysis

M3 - SCORING: Journal article

C2 - 11918085

VL - 19

SP - 71

EP - 77

JO - CLIN EXP METASTAS

JF - CLIN EXP METASTAS

SN - 0262-0898

IS - 1

ER -